Viroclinics-DDL, employing a total of over 390 scientists and experts, offers a broad range of virology related services in the field of non-clinical and clinical trials, clinical diagnostics, assay development and clinical trial logistics enabling the development of antiviral drugs, vaccines, and other therapies. The acquisition fits perfectly into Cerba HealthCare’s strategy aimed at further strengthening its position in the entire diagnostics and clinical trial laboratory services value chain, while providing the most relevant services to patients, the medical community and healthcare industry players. Within the Cerba Research division, Viroclinics-DDL will be able to further broaden its services and access new markets in North America, Asia, and Africa.
Osborne Clarke has assisted Viroclinics-DDL and its management for years, on day to day work and high profile transactions, including the sale of Viroclinics by Gilde Healthcare to Parcom Capital, the subsequent sale by Parcom Capital to Summit Partners and, most recently, the add-on acquisition of DDL Diagnostic Laboratory.
The Osborne Clarke team which advised management in this transaction, was led by Partner Herke van Hulst and included Senior Associate Niels Dolk, Associate Angela Saldanha, Partner / notary Cars-Jan van Gool, and civil law notaries Arlette Vrolijk and Eveline Leijen, all from Osborne Clarke Amsterdam. From the Osborne Clarke London office, Associate Director Seamus McKimm and Associate Ben Parker were part of the team.
Osborne Clarke’s international life sciences and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable M&A work from the team in Amsterdam includes advising the shareholders on the sale of MILabs to Rigaku, Terumo Corporation on the acquisition of Quirem Medical, assisting on the sale of Isobionics to BASF and the sale of Breath Therapeutics to Zambon.